Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy

被引：130
|
作者：
Thibodeau, Jacques [1 ]
Bourgeois-Daigneault, Marie-Claude [1 ]
Lapointe, Rejean [2 ,3 ]
机构：
[1] Univ Montreal, Dept Microbiol & Immunol, Lab Immunol Mol, Montreal, PQ H3C 3J7, Canada
[2] Univ Montreal, Notre Dame Hosp, CRCHUM, Montreal, PQ H3C 3J7, Canada
[3] Univ Montreal, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada
来源：
ONCOIMMUNOLOGY | 2012年 / 1卷 / 06期
基金：
加拿大健康研究院;
关键词：
cancer; HLA; immunotherapy; MHC Class II; tumor; vaccine; CD4(+) T-CELLS; CHRONIC LYMPHOCYTIC-LEUKEMIA; INVARIANT CHAIN; HLA-DR; TUMOR-CELLS; METASTATIC MELANOMA; IMMUNE-RESPONSE; B-CELLS; EXPRESSION; CIITA;
D O I：
10.4161/onci.21205
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The success of immunotherapy relies on the participation of all arms of the immune system and the role of CD4(+) T lymphocytes in preventing tumor growth is now well established. Understanding how tumors evade immune responses holds the key to the development of cancer immunotherapies. In this review, we discuss how MHC Class II expression varies in cancer cells and how this influences antitumor immune responses. We also discuss the means that are currently available for harnessing the MHC Class II antigen presentation pathway for the development of efficient vaccines to activate the immune system against cancer.
引用
收藏
页码：908 / 916
页数：9
相关论文
共 50 条
  • [1] Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy
    Martinez-Gomez, J. M.
    Johansen, P.
    Rose, H.
    Steiner, M.
    Senti, G.
    Rhyner, C.
    Crameri, R.
    Kuendig, T. M.
    ALLERGY, 2009, 64 (01) : 172 - 178
  • [2] The endogenous pathway of MHC class II antigen presentation
    Lechler, R
    Aichinger, G
    Lightstone, L
    IMMUNOLOGICAL REVIEWS, 1996, 151 : 51 - 79
  • [3] Transcriptional regulation of the MHC class II antigen presentation pathway
    Boss, JM
    Jensen, PE
    CURRENT OPINION IN IMMUNOLOGY, 2003, 15 (01) : 105 - 111
  • [4] Targeting Antigen to MHC Class II Molecules Promotes Efficient Cross-Presentation and Enhances Immunotherapy
    Dickgreber, Nina
    Stoitzner, Patrizia
    Bai, Yan
    Price, Kylie M.
    Farrand, Kathryn J.
    Manning, Kristy
    Angel, Catherine E.
    Dunbar, P. Rod
    Ronchese, Franca
    Fraser, John D.
    Baeckstroem, B. Thomas
    Hermans, Ian F.
    JOURNAL OF IMMUNOLOGY, 2009, 182 (03): : 1260 - 1269
  • [5] B-cell antigen receptor signaling requirements for targeting antigen to the MHC class II presentation pathway
    Clark, MR
    Massenburg, D
    Siemasko, K
    Hou, P
    Zhang, M
    CURRENT OPINION IN IMMUNOLOGY, 2004, 16 (03) : 382 - 387
  • [6] HLA-DM and the MHC class II antigen presentation pathway
    Jensen, PE
    Weber, DA
    Thayer, WP
    Chen, XJ
    Dao, CT
    IMMUNOLOGIC RESEARCH, 1999, 20 (03) : 195 - 205
  • [7] HLA-DM and the MHC class II antigen presentation pathway
    Peter E. Jensen
    Dominique A. Weber
    Wesley P. Thayer
    Xinjian Chen
    Chin T. Dao
    Immunologic Research, 1999, 20 : 195 - 205
  • [8] Inhibition of the MHC class II antigen presentation pathway by human cytomegalovirus
    Johnson, DC
    Hegde, NR
    VIRAL PROTEINS COUNTERACTING HOST DEFENSES, 2002, 269 : 101 - 115
  • [9] Targeting antigen to MHC class I and class II antigen presentation pathways for malaria DNA vaccines
    Dobano, Carlota
    Rogers, William O.
    Gowda, Kalpana
    Doolan, Denise L.
    IMMUNOLOGY LETTERS, 2007, 111 (02) : 92 - 102
  • [10] Antigen targeting to MHC class I and MHC class Ii presentation pathways of enterocytes in inflammatory bowel disease
    Büning, J
    Schmitz, M
    Hundorfean, G
    Strobel, S
    Zimmer, KP
    Gebert, A
    Ludwig, D
    GASTROENTEROLOGY, 2005, 128 (04) : A502 - A502
12345